Stay updated on Pembrolizumab for Metastatic Anal Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Anal Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for Metastatic Anal Cancer Clinical Trial page
- Check3 days agoChange DetectedThe footer revision number changed from v3.7.2 to v3.8.0 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check10 days agoChange DetectedA site-wide NIH notice says agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check17 days agoChange DetectedThe site footer revision label changed from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error page.SummaryDifference0.2%

- Check24 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check45 days agoChange DetectedThe study record page now shows a 403 Forbidden error instead of the study details. This indicates the content is currently inaccessible and the site presents a standard access-denied screen with navigation and footer.SummaryDifference18%

- Check67 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6, indicating the page has been revised. This reflects an updated version of the ClinicalTrials.gov study record page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Metastatic Anal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Anal Cancer Clinical Trial page.